migraines

New Jersey: Migraine, Chronic Pain Patients Seek Approval To Use Medical Marijuana

weed in a jar.jpg

by Derrick Stanley
Hemp News

A health department panel in New Jersey will consider adding chronic pain and other ailments to the state's list of conditions that can be treated with medical marijuana.

The public is invited to attend and make comments at the hearing scheduled for February 22. The panel will consist of eight doctors, pharmacists, and nurses who were appointed by Health Commissioner Cathleen Bennett nearly one year ago.

“I think cannabis can replace all three of the medications I take for anxiety, migraines, and chronic pain,” said Bob Kane, 56, a retired landscaper from Ocean View who had his family doctor write letters to the department supporting his request in three petitions he submitted.

68 people sent petitions to the panel. Migraines, autism, lupus, and opiate-addiction disorder were some of the 20 or so ailments mentioned in the petitions.

The medical marijuana program currently allows patients who have terminal cancer, multiple sclerosis, seizure disorders, glaucoma, and several other conditions to obtain cannabis if recommended by their doctor.

U.S.: Former GW Pharmaceuticals Advisor Discusses Future of Medical Cannabis

DrEthanRusso[Ganjapreneur]

Cannabis business website Ganjapreneur has announced its latest podcast episode, which features prominent medical marijuana researcher Dr. Ethan Russo in a conversation about his research regarding the Endocannabinoid System — a unique system found in all vertebrates, including humans, which promotes homeostasis and a biological balance across bodily functions.

In the interview, Ganjapreneur podcast host Shango Los asks Dr. Russo about Endocannabinoid Deficiency (ECD) and the potential for it to be treated with cannabis. As Russo explains, ECD is just coming into general awareness now as a cause behind several conditions including Migraines, Fibromyalgia, Irritable Bowel Syndrome, Phantom Limb Pain, Infantile colic, Glaucoma, PTSD, Bipolar disease and others.

When used as a form of treatment, "A lot of what THC does is paralleled by the effects of... natural chemicals in the body that everyone has," Dr. Russo explained.

Before going public with his research, Dr. Russo worked for years as senior medical advisor for GW Pharmaceuticals; there, he oversaw three separate clinical trials for Sativex, one of the world's first cannabinoid-based medicines to be approved for public use.

Today, he is medical director at Phytecs, a company specializing in the production of cannabis-based treatments related to the endocannabinoid system. Due to legal complications and concerns over the federal legality of his work, Dr. Russo only began to speak publicly about his research earlier this year.

Wisconsin: Company Readies Hemp-Based Non-Prescription Cannabinoid Medication For Epilepsy

PuraMedBioScience(logo)

PuraMed BioScience, Inc., a company which researches, develops, and markets over-the-counter (OTC) medicinal and healthcare products on Friday announced it is nearing the completion of development of its new non-prescription, hemp-based, homeopathic medication for treatment of epilepsy symptoms including seizures and seizure-related headaches.

Both epilepsy and migraines appear to be triggered by the same cortical spreading depression (CSD) in the brain; the difference is the rate of reaction. This may be why many people who suffer from migraines are prescribed epilepsy medications.

The third most common neurological disorder in the US, epilepsy affects about 2.7 million people, with children and older adults being most susceptible. The condition also causes up to 50,000 sudden deaths each year.

Recent research has shown cannabidiol (CBD), a non-psychoactive cannabinoid found in both hemp and marijuana varieties of cannabis, to be an effective therapy in the treatment of epilepsy symptoms.

"By incorporating standardized hemp oil into our current patented, over-the-counter migraine relief formula, MigraPure, we believe we can offer relief to people who not only suffer with migraines, but also offer relief to people who have seizure-related headaches and other epilepsy-type symptoms," said Russ Mitchell, CEO at PuraMed BioScience.

Syndicate content